| # | Drug | Count |
|---|---|---|
| 0 | PEMBROLIZUMAB | 12384 |
| 1 | NIVOLUMAB | 9963 |
| 2 | CARBOPLATIN | 6347 |
| 3 | ENZALUTAMIDE | 5499 |
| 4 | EVEROLIMUS | 4746 |
| 5 | LETROZOLE | 4614 |
| 6 | PACLITAXEL | 4514 |
| 7 | FULVESTRANT | 4341 |
| 8 | CAPECITABINE | 4033 |
| 9 | PACLITAXEL (AIBUMIN-BOUND) | 3938 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | STREPTOZOCIN | 63 | 0.2739 |
| 1 | AFATINIB | 1696 | 0.2561 |
| 2 | GEFITINIB | 1824 | 0.2029 |
| 3 | PRALATREXATE | 118 | 0.1815 |
| 4 | CERITINIB | 430 | 0.1804 |
| 5 | BELZUTIFAN | 262 | 0.1474 |
| 6 | FULVESTRANT | 4341 | 0.1295 |
| 7 | RAMUCIRUMAB | 817 | 0.1293 |
| 8 | ZONGERTINIB | 21 | 0.1257 |
| 9 | PEMBROLIZUMAB | 12384 | 0.1141 |
| # | Drug class | Count |
|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 22836 |
| 1 | Kinase Inhibitor [EPC] | 20889 |
| 2 | Platinum-based Drug [EPC] | 10770 |
| 3 | Corticosteroid [EPC] | 7606 |
| 4 | Nucleoside Metabolic Inhibitor [EPC] | 7491 |
| 5 | Microtubule Inhibitor [EPC] | 6968 |
| 6 | Aromatase Inhibitor [EPC] | 6548 |
| 7 | Androgen Receptor Inhibitor [EPC] | 5913 |
| 8 | Alkylating Drug [EPC] | 4940 |
| 9 | mTOR Inhibitor Immunosuppressant [EPC] | 4801 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 22836 | 0.2316 |
| 1 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 817 | 0.1293 |
| 2 | Estrogen Receptor Antagonist [EPC] | 4509 | 0.1112 |
| 3 | Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC] | 61 | 0.1013 |
| 4 | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | 2129 | 0.0993 |
| 5 | CTLA-4-directed Blocking Antibody [EPC] | 4144 | 0.0859 |
| 6 | Programmed Death Ligand-1 Blocker [EPC] | 1762 | 0.0816 |
| 7 | Androgen Receptor Inhibitor [EPC] | 5913 | 0.0800 |
| 8 | Claudin 18.2-directed Cytolytic Antibody [EPC] | 117 | 0.0767 |
| 9 | Lymphocyte Activation Gene-3 Blocker [EPC] | 35 | 0.0680 |